1.2. Pediatrics

Proventil HFA, Ventolin HFA, ProAir RespiClick, ProAir Digihaler, and generic albuterol HFA are FDA-approved for use in children 4 years of age and older for prevention/treatment of bronchospasm and prevention of exercise-induced bronchospasm^1-6. Levalbuterol is FDA-approved for use in children 4 years of age and older for prevention/treatment of bronchospasm^{1, 7}.;

To prevent EIB in pediatric patients 4 years of age and older, two albuterol 90 mcg inhalations are administered at least 15 to 30 minutes before exercise on an as-needed basis.

Combination therapy with ipratropium and albuterol is not FDA-approved for use in pediatric patients as safety and efficacy in this patient population have not been established.

Pediatric dosages for short-acting beta2-agonists used to manage acute asthma exacerbations are summarized in Table 3. Dosages exceeding these recommendations will be reviewed.